Elderly patients face greater perioperative risks and postoperative mortality, so careful selection of surgical candidates is imperative.
A recent study found that only 12% of patients older than 80 years received radical treatment for invasive disease.
A pathologist was unable to determine if a bladder tumor was muscle invasive because biopsy samples did not include muscle tissue.
Modern diagnostics such as endoscopy have supplanted traditional methods of diagnosing UTUC.
These subtypes have clinically meaningful differences in outcome, according to investigators.
No reduction in risk with increasing duration of metformin use relative to sulfonylureas.
Seventeen percent of Americans think that there is nothing people can do to change their risk.
In a study, bladder tumors recurred in 14.5% of patients following a five-year tumor-free period.
Study demonstrates an association with micropapillary urothelial carcinoma.
Information gained through image cytometry could shed light on disease recurrence and progression.
Death from PCa is down 45% from peak rates, but more than 29,000 men are projected to die from PCa in 2014.
Group proposes standard definition of progression in nonmuscle invasive bladder cancer.
It is associated with a reduced risk of cancer recurrence and progression, new findings suggest.
It also increases the risk of death from bladder cancer, according to a new study.
New findings identify STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not metastasize.
More than half of all venous thromboembolism events were diagnosed after patient discharge.
Study suggests benefit of adding of emetine dihydrochloride to treatment.
Increased risk in first year after diagnosis limited to those with fewest doc visits in previous two years.